The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | A personalized prediction model to risk stratify patients with MDS
Myelodysplastic syndrome (MDS) patients have very heterogeneous outcomes in terms of overall survival. Here, Aziz Nazha, MD, of the Cleveland Clinic, Cleveland, OH, discusses a personalized prediction model that uses clinical-, molecular-, and transplant-related data predict the probability of survival for individual MDS patients, aiding HCPs and patients in their decision-making prior to transplant. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
